Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

INCLUSION CRITERIA, RECIPIENT WITH MYELODYSPLASTIC SYNDROME (MDS) * Diagnosis of MDS classifiable by the World Health Organization (WHO) on the basis of: * Refractory anemia * Refractory anemia with excess blasts-1 * Refractory anemia with excess blasts-2 * Refractory cytopenia with multi-lineage dysplasia * Refractory cytopenia with multi-lineage dysplasia and ringed sideroblasts * Chronic myelomonocytic leukemia (CMML) * MDS transformed to acute leukemia * MDS-unclassified * Participants with advanced MDS must have \< 10% marrow blasts prior to receiving conditioning with TLI/ATG, documented by marrow examination within 1 month prior. * Participants with evolution to acute leukemia (AML) must be in a morphologic leukemia free-state (MLFS) with blasts \< 5% INCLUSION CRITERIA, RECIPIENT WITH MYELOPROLIFERATIVE DISORDER (MPD) * Diagnosis of MPD on the basis of: * Idiopathic myelofibrosis * Polycythemia vera * Essential thrombocythemia * Chronic myelomonocytic leukemia (CML) * CML, Philadelphia chromosome-negative * Chronic neutrophilic leukemia * Chronic eosinophilic leukemia * Hypereosinophilic cyndrome * Systemic mastocytosis * \< 10% marrow blasts prior to receiving conditioning with TLI/ATG, documented by marrow examination within 1 month prior. * Participants with evolution to acute leukemia (AML) must be in a morphologic leukemia free-state (MLFS) with blasts \< 5%. Presence of residual dysplastic features following cytoreductive therapy is acceptable. INCLUSION CRITERIA, RECIPIENT WITH THERAPY-RELATED MYELOID NEOPLASM (t MDS) * \< 10% marrow blasts prior to receiving conditioning with TLI/ATG, documented by marrow examination within 1 month prior. * Morphologic leukemia free-state with blasts \< 5 %. * Age \> 50 years, or \< 50 years of age but at high-risk for regimen-related toxicity associated with conventional myeloablative transplants due to pre-existing medical conditions or prior therapy * Availability of a fully HLA-matched or single antigen/allele mismatched sibling or unrelated donor * Prior malignancy diagnosed \> 5 years ago without evidence of disease, or \< 5 years ago with life expectancy of \> 5 years are eligible (prior malignancy is not a requirement) INCLUSION CRITERIA, DONOR * Donors must be HLA-matched or one allele mismatched. * Donor age \< 75 (EXCEPTION by Principal Investigator discretion) * Must consent to PBSC mobilization with G-CSF; apheresis; and collection and donation of plasma * Donor must consent to placement of a central venous catheter in the event that peripheral venous access is limited. EXCLUSION CRITERIA, RECIPIENT Any of the following: * Uncontrolled CNS involvement with disease * Pregnant * Cardiac function: ejection fraction (EF) \< 35% or uncontrolled cardiac failure * Diffusing capacity of the lungs for carbon monoxide (DLCO) \< 40% predicted * Bilirubin \> 3 mg/dL * Aspartate aminotransferase (AST) \> 3x the upper limit of normal (ULN) * Alanine aminotransferase (ALT) \> 3x ULN * Estimated creatinine clearance \< 50 mL/min * Karnofsky performance score (KPS) \< 70% * Documented fungal disease that is progressive despite treatment * HIV-positive EXCLUSION CRITERIA, DONOR Any of the following: * Identical twin to recipient * Pregnant or lactating * Prior malignancy within the preceding 5 years (EXCEPTION: non-melanoma skin cancers) * HIV seropositivity